GenArraytion’s Multiplex PCR Assays to be Evaluated on PositiveID’s Firefly Dx Prototype System
DELRAY BEACH, Fla., Aug. 04, 2015 (GLOBE NEWSWIRE) — PositiveID Corporation (“PositiveID” or “Company”) (OTCQB:PSID), a developer of biological detection and diagnostics solutions, and GenArraytion Inc., a developer of real-time multiplex PCR (polymerase chain reaction) assays, today announced that they have entered into an agreement to partner and evaluate GenArraytion’s assays on PositiveID’s Firefly Dx PCR breadboard prototype pathogen detection system (“prototype system”).
Firefly Dx is designed to provide real-time, accurate diagnostic results in a handheld device, thereby leading to treatment scenarios at the point of need that are not possible with existing systems, which require lab-based equipment and can take hours or even days to provide results. Firefly’s applications include point-of-need, lab-quality, detection of pathogenic organisms; agricultural and food screening in both domestic sectors and developing countries; and detection of biological agents associated with weapons of mass destruction.
GenArraytion’s MultiFLEX Bioassays™ for clinically relevant pathogens and bio-threat agents provide a significant advance in multiplexing flexibility, with up to 20 DNA and/or RNA targets in a single assay panel that can be mixed and matched. They are readily configurable, highly specific and sensitive multiplex PCR assays ready for use in real-time and bead-based end-point platforms. MultiFLEX Bioassays™ are developed for clinical pathogens and veterinary disease agents as well as food or water-borne pathogens and biological threats.
Dr. R. Paul Schaudies, CEO of GenArraytion, stated, “We are very interested in the work PositiveID is doing with its Firefly Dx, which could significantly advance the capabilities of the real-time PCR market, and we are pleased to partner with them to test our assays on this exciting and essential point-of-need technology platform.”
“GenArraytion’s competencies and real-time PCR assays are first-rate, which is evidenced by their world-class customer base, and we believe our cooperative experience will provide us an opportunity to further advance the development and testing of Firefly Dx,” said Lyle Probst, President of PositiveID.
About GenArraytion, Inc.
Based in Rockville, MD, GenArraytion, Inc. is a privately held, Veteran owned, small business dedicated to the development and commercialization of multiplexed molecular assays for infectious diseases. GenArraytion is dedicated to improving healthcare through the development and distribution of treatment-guiding molecular assays on a variety of platforms. GenArraytion develops molecular assays for biodefense applications, infectious disease markets, environmental and forensic applications, and veterinary markets. For more information, visit www.genarraytion.com.
About PositiveID Corporation
PositiveID Corporation is an emerging growth company and developer of biological detection systems for America’s homeland defense industry as well as rapid biological testing. PositiveID is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats and analyze biological samples. For more information on PositiveID, please visit http://www.psidcorp.com, or connect with PositiveID on Twitter, Facebook or LinkedIn.
Statements about PositiveID’s future expectations, including the likelihood that its cooperative experience with GenArraytion will provide it an opportunity to further advance the development and testing of Firefly Dx; the likelihood that Firefly Dx is designed to provide real-time, accurate diagnostic results in a handheld device, thereby leading to treatment scenarios at the point of need that are not possible with existing systems, which require lab-based equipment, highly trained personnel, and can take hours or even days to provide results; constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID’s actual results could differ materially from expected results. These risks and uncertainties include, without limitation, the Company’s ability to target the bio-threat detection and rapid medical testing sectors; the Company’s ability to complete the development of its Firefly Dx system; the Company’s ability to win government contracts; as well as other risks. Additional information about these and other factors that could affect the Company’s business is set forth in the Company’s various filings with the Securities and Exchange Commission, including those set forth in the Company’s 10-K filed on March 30, 2015, and 10-Qs filed on May 15, 2015, November 17, 2014, and August 14, 2014, under the caption “Risk Factors.” The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.